Pharmacy verification
USP <797> Sterile Compounding Explained
USP <797> is the compendial standard governing sterile compounding — air quality, personnel practices, environmental monitoring, and beyond-use dating. Compliance is a claim about process, not about any individual batch, and it is not FDA approval. Ask whether compliance has been independently assessed and by whom.
What the standard covers
USP General Chapter <797> sets requirements for compounding sterile preparations. Its subject matter is process control: the classification and monitoring of the compounding environment, personnel training and garbing, aseptic technique, cleaning and disinfection, and the assignment of beyond-use dates that limit how long a preparation may be used.
It exists because sterile injectables carry contamination risk that non-sterile preparations do not, and because that risk has produced deaths — the 2012 fungal meningitis outbreak that led to the 503A/503B framework originated in contaminated compounded injections.
Why beyond-use dating matters to you
A compounded sterile preparation carries a beyond-use date derived from the standard, not an expiry date derived from stability testing of an approved product. Those are different things.
If you receive a multi-month supply of a compounded injectable, the beyond-use date on the vial is worth checking against the length of your supply. Ask what it is before ordering a twelve-month quantity.
What a compliance claim establishes
That the facility states it operates to the standard. Whether that has been independently assessed is a separate question, and the phrase "USP <797> compliant" on a marketing page does not answer it.
State boards enforce the standard as part of licensure in many jurisdictions, and FDA inspection of 503B facilities covers CGMP, which is a distinct and generally more demanding framework. Accreditation bodies assess against it too.
The questions that produce information
- Has USP <797> compliance been independently assessed, by whom, and when?
- What is the beyond-use date on my preparation, and how was it determined?
- Is environmental monitoring performed, and how often?
- Is the product single-dose or multi-dose, and what is the in-use period once opened?
The last one connects to a documented harm pattern: multi-dose vials require the patient to measure each dose, and dosing errors from self-measurement are among the adverse events the FDA has cited in its enforcement posture toward compounded GLP-1s.
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
- FDA registered outsourcing facilitiesConfirms a facility is currently registered under 503B, and links the searchable product report database. Registration is not FDA approval and is not evidence of CGMP compliance.
- FDA outsourcing facility registration Q&AThe agency's own explanation of exactly what registration does and does not mean. Worth reading before accepting any provider's characterisation of its pharmacy.
- NABP directory of state boards of pharmacyRoutes you to the board that licenses a pharmacy, and to its licensee and nonresident registers. Check the licence is current, not merely present.
- FSMB directory of state medical boardsRoutes you to the board that licenses a prescriber, and to its public licence lookup. An NPI number is identity in a national registry, not a licence.
Every one of these is the register held by the body that issues the credential. A claim checked against the page that made it has not been checked.
| Claim | Proves | Does not prove |
|---|---|---|
| FDA-registered outsourcing facility | A registration was filed | That any product is FDA-approved |
| State pharmacy licence | A board issued a licence | That it is current — check it |
| Accreditation | A voluntary assessment was passed | Batch quality or product approval |
| USP <797> compliance | A sterile compounding standard is claimed | That it was independently audited |
| Third-party tested | Something was tested | What, by whom, or how often, without a certificate |
| NPI number | Identity in a national registry | A current licence in any state |
| FDA-approved compounded medicine | Nothing — the category does not exist | Treat as a red flag |
Providers publishing terms openly are easier to hold to a written answer. NexLife states its pricing and dose-coverage on its own plan pages before intake, which is why its records are the six we marked verified — though it has not named its fulfilling pharmacy to us either. Its published plans.
Questions readers actually ask
Is USP <797> compliance the same as FDA approval?
No. It is a compendial standard for sterile compounding process. No compounded product is FDA-approved.
What is a beyond-use date?
The date after which a compounded sterile preparation should not be used, derived from the standard rather than from stability testing of an approved product. Check it against the length of any bulk supply.
Related on this site
- Pharmacy verification centrePharmacies
- How to Verify a Compounding PharmacyPharmacies
- 503A Compounding Pharmacy DirectoryPharmacies
- 503B Outsourcing Facility DirectoryPharmacies
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- 503A vs 503B: A Patient Verification ChecklistJournal
- 503A vs 503B CompoundingComparisons
- What PCAB Accreditation MeansPharmacies
GLP-1 Tirzepatide Review. “USP <797> Sterile Compounding Explained.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/pharmacies/usp-797-sterile-compounding/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.